Published in Immunol Lett on November 17, 2015
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | NCT00923351
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer | NCT01572493
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | NCT01369888
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | NCT01134250
IL-21-Expanded NK Cells for Induction of Acute Myeloid Leukemia (AML) | NCT01787474
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients | NCT02395822
Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis. Cytokine (2016) 0.75
Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein. Cancer Res (2016) 0.75
LYG1 exerts antitumor function through promoting the activation, proliferation, and function of CD4(+) T cells. Oncoimmunology (2017) 0.75
NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27. Oncotarget (2017) 0.75
The making of a killer (T cell). Oncotarget (2017) 0.75
Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res (2017) 0.75
Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges. Biomed Res Int (2017) 0.75
Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 15.73
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell (1993) 11.95
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med (2000) 9.78
Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol (1999) 8.98
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A (2001) 6.91
Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell (1993) 6.83
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature (2003) 6.78
Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science (1994) 6.65
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol (2006) 6.22
IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity (2002) 6.10
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J (1994) 5.69
Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature (1988) 5.50
IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol (2007) 5.31
IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem (2007) 4.77
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60
Cloning of the gamma chain of the human IL-2 receptor. Science (1992) 4.50
Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer (2004) 4.43
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet (1998) 4.32
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97
Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol (2011) 3.91
Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) 3.88
Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J (1995) 3.59
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science (1994) 3.46
Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat Immunol (2000) 3.42
IL-7 enhances the survival and maintains the size of naive T cells. J Immunol (2001) 3.39
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Transcriptional regulation of the IL-2 gene. Curr Opin Immunol (1995) 3.14
Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci U S A (1997) 3.06
Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology (2015) 3.04
Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity (1998) 3.03
Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci U S A (2004) 2.98
The molecular basis of IL-21-mediated proliferation. Blood (2007) 2.90
Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity (2009) 2.89
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 2.86
Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med (2004) 2.78
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med (2011) 2.59
Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2.51
A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A (1994) 2.51
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood (2009) 2.50
Tumor-host interactions: a far-reaching relationship. J Clin Oncol (2010) 2.48
A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest (1997) 2.37
The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science (1987) 2.35
Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression. Nat Immunol (2008) 2.31
IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol (2003) 2.28
Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity (2012) 2.16
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature (2012) 2.08
How do regulatory T cells work? Scand J Immunol (2009) 2.02
Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood (2009) 2.00
Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res (2010) 1.92
Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature (1985) 1.85
In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res (2003) 1.81
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood (2013) 1.79
NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol (2001) 1.76
IL-2: the first effective immunotherapy for human cancer. J Immunol (2014) 1.71
IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol (2003) 1.70
The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry (2002) 1.68
Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci (2011) 1.64
Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov (2014) 1.62
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol (2008) 1.60
Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood (2011) 1.56
Activated T cells secrete an alternatively spliced form of common γ-chain that inhibits cytokine signaling and exacerbates inflammation. Immunity (2014) 1.51
Advances in tenascin-C biology. Cell Mol Life Sci (2011) 1.50
Calcium-dependent activation of interleukin-21 gene expression in T cells. J Biol Chem (2005) 1.47
IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc Natl Acad Sci U S A (2003) 1.45
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res (2010) 1.44
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol (2014) 1.38
Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. J Exp Med (1996) 1.30
The effect of in vivo IL-7 deprivation on T cell maturation. J Exp Med (1995) 1.30
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med (2011) 1.27
B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood (2006) 1.25
Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. J Immunol (1997) 1.24
Treatment of metastatic renal cell carcinoma. Nat Rev Urol (2010) 1.24
Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol (2001) 1.24
Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood (2013) 1.24
Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene (2012) 1.23
Functions of γC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol (2009) 1.22
Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther (2003) 1.18
Signaling through the interleukin 2 receptor beta chain activates a STAT-5-like DNA-binding activity. Proc Natl Acad Sci U S A (1995) 1.16
Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res (2007) 1.16
Cytokines of the γ(c) family control CD4+ T cell differentiation and function. Nat Immunol (2012) 1.12
Interleukin-7 can induce the activation of Jak 1, Jak 3 and STAT 5 proteins in murine T cells. Eur J Immunol (1995) 1.11
IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood (2012) 1.10
The Src-family kinase, Fyn, regulates the activation of phosphatidylinositol 3-kinase in an interleukin 2-responsive T cell line. J Exp Med (1994) 1.10
Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol (2011) 1.09
IL-2 binding activates a tyrosine-phosphorylated phosphatidylinositol-3-kinase. J Immunol (1991) 1.07
The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity (2013) 1.06
Identification of IL-7-producing cells in primary and secondary lymphoid organs using IL-7-GFP knock-in mice. J Immunol (2012) 1.05
The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol (2006) 1.04
Chemokines in cancer. Cancer Immunol Res (2014) 1.03
Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J (2010) 1.03
Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol (2012) 1.02
Innate-Adaptive Immune Crosstalk. J Immunol Res (2015) 0.75